Developer of a multi-omics platform designed to detect cancer through a routine blood draw.
Decision/Risk Analysis📍 Brisbane, CAFounded 2014
Current Valuation
$2.2B
as of 2024-Q1
UNICORN
Developer of a multi-omics platform designed to detect cancer through a routine blood draw.
Company Profile
Founded
2014
HQ
Brisbane, CA
Employees
392
Total Raised
$1.4B
Last Round
Later Stage VC — $254M (Feb 2024)
IPO Status
private
Fundraising Status
Later Stage VC · $254M · 2y 6mo ago
privateTotal raised $1.4B
Secondary Market
Implied price / share
$1.48
Last round price / share
$7.4
vs last round
-80.0%
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Later Stage VC
$254M
Feb 2024
—
$2.2B
Health CareBiotechnologyPersonal HealthHealth Diagnostics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2024-Q1. Refreshed quarterly.